Improvement of sinus disease in cystic fibrosis with ivacaftor therapy

Am J Respir Crit Care Med. 2014 Aug 15;190(4):468. doi: 10.1164/rccm.201403-0595IM.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Acetates / therapeutic use
  • Adult
  • Aminophenols / therapeutic use*
  • Androstadienes / therapeutic use
  • Anti-Allergic Agents / therapeutic use
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / drug therapy*
  • Female
  • Fluticasone
  • Humans
  • Leukotriene Antagonists / therapeutic use
  • Paranasal Sinus Diseases / complications*
  • Paranasal Sinus Diseases / drug therapy*
  • Quinolines / therapeutic use
  • Quinolones / therapeutic use*
  • Rhinitis, Allergic, Perennial / complications
  • Rhinitis, Allergic, Perennial / drug therapy
  • Treatment Outcome
  • Young Adult

Substances

  • Acetates
  • Aminophenols
  • Androstadienes
  • Anti-Allergic Agents
  • Leukotriene Antagonists
  • Quinolines
  • Quinolones
  • ivacaftor
  • Fluticasone
  • montelukast